This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Demunter, A. Articles by van den Oord, J. J. Search for Related Content PubMed PubMed Citation Articles by Demunter, A. Articles by van den Oord, J. J.

A Novel N-ras Mutation in Malignant Melanoma Is Associated with Excellent Prognosis¹

Laboratory of Morphology and Molecular Pathology, Departments of Pathology [A. D., L. L., C. D. W-P., J. J. v. d. O.], Surgical Oncology [M. S.], and Dermatology [H. D.], Katholieke Universiteit Leuven, Leuven 3000, Belgium; Human Genome Laboratory, Center for Human Genetics, Flanders Interuniversity Institute for Biotechnology, Leuven 3000, Belgium [M. B.]; Max-Planck Institute, Dortmund 44227, Germany [M. R. A.]; and European Molecular Biology Laboratory, Heidelberg 69120, Germany [K. S.]

Mutations in the ras gene are key events in the process of carcinogenesis; in particular, point mutations in codon 61 of exon 2 of the N-ras gene occur frequently in malignant melanoma (MM). We searched for point mutations in the N-ras gene in a large series of primary and metastatic MM from 81 different retrospectively selected patients using the very sensitive denaturing gradient gel electrophoresis technique, followed by sequencing. The classical codon 12 and codon 61 mutations were found in 21 and 17% of the cases, respectively. No codon 13 mutation was found. A novel mutation at codon 18 of exon 1, consisting of a substitution of alanine (GCA) by threonine (ACA), was found in 15% of the primary MMs but in none of the metastatic MMs. All of the other cases were free of mutations. Using microdissected cells from distinctive MM growth phases as source of DNA for mutation analysis, this particular N-ras exon 1 mutation at codon 18 was already present in the radial growth phase and preserved throughout the successive growth phases; it was also found in a dysplastic nevi in continuity with a MM, indicating a clonal relationship between both lesions. Our findings also illustrate the clonal relationship between the distinctive growth phases in MM and suggest the codon 18 mutation to occur early in MM development. The MM in patients with this mutation were significantly thinner than those without a codon 18 mutation (P = 0.0257). Statistical analysis, comparing the group of codon 18 patients with the group of patients with the classical mutations and without mutations, revealed a highly significant difference in overall outcome. The cumulative probability of developing metastasis was significantly lower for the group patients with a codon 18 mutation (P = 0.0130). We can thus conclude that this codon 18 mutation identifies a group of patients with better prognosis than patients with melanoma that harbor wild-type sequence or classical activating point mutations in codon 12 or 61.

Preliminary nucleotide binding measurements could not detect a difference between wild-type Ras protein and the mutant Ras(A18T) protein. However, for a precise elucidation of the role of the N-Ras(A18T) mutant in melanoma, additional studies aimed to measure the affinity to guanine nucleotide exchange factors and GTPase-activating proteins are needed.

This article has been cited by other articles:

				K. Omholt, A. Platz, L. Kanter, U. Ringborg, and J. Hansson NRAS and BRAF Mutations Arise Early during Melanoma Pathogenesis and Are Preserved throughout Tumor Progression Clin. Cancer Res., December 15, 2003; 9(17): 6483 - 6488. [Abstract] [Full Text] [PDF]

				K. Jorgensen, R. Holm, G. M. Maelandsmo, and V. A. Florenes Expression of Activated Extracellular Signal-Regulated Kinases 1/2 in Malignant Melanomas: Relationship with Clinical Outcome Clin. Cancer Res., November 1, 2003; 9(14): 5325 - 5331. [Abstract] [Full Text] [PDF]

				F. Cruz III, B. P. Rubin, D. Wilson, A. Town, A. Schroeder, A. Haley, T. Bainbridge, M. C. Heinrich, and C. L. Corless Absence of BRAF and NRAS Mutations in Uveal Melanoma Cancer Res., September 15, 2003; 63(18): 5761 - 5766. [Abstract] [Full Text] [PDF]

				M. Eskandarpour, J. Hashemi, L. Kanter, U. Ringborg, A. Platz, and J. Hansson Frequency of UV-Inducible NRAS Mutations in Melanomas of Patients With Germline CDKN2A Mutations J Natl Cancer Inst, June 4, 2003; 95(11): 790 - 798. [Abstract] [Full Text] [PDF]

				M. Spugnardi, S. Tommasi, R. Dammann, G. P. Pfeifer, and D. S. B. Hoon Epigenetic Inactivation of RAS Association Domain Family Protein 1 (RASSF1A) in Malignant Cutaneous Melanoma Cancer Res., April 1, 2003; 63(7): 1639 - 1643. [Abstract] [Full Text] [PDF]

				K. L. Rossman, D. K. Worthylake, J. T. Snyder, L. Cheng, I. P. Whitehead, and J. Sondek Functional Analysis of Cdc42 Residues Required for Guanine Nucleotide Exchange J. Biol. Chem., December 20, 2002; 277(52): 50893 - 50898. [Abstract] [Full Text] [PDF]

				A. Sivertsson, A. Platz, J. Hansson, and J. Lundeberg Pyrosequencing as an Alternative to Single-Strand Conformation Polymorphism Analysis for Detection of N-ras Mutations in Human Melanoma Metastases Clin. Chem., December 1, 2002; 48(12): 2164 - 2170. [Abstract] [Full Text] [PDF]

				K. Omholt, S. Karsberg, A. Platz, L. Kanter, U. Ringborg, and J. Hansson Screening of N-ras Codon 61 Mutations in Paired Primary and Metastatic Cutaneous Melanomas: Mutations Occur Early and Persist throughout Tumor Progression Clin. Cancer Res., November 1, 2002; 8(11): 3468 - 3474. [Abstract] [Full Text] [PDF]

				J. Martin-Hernandez, A. B. Sorensen, and F. S. Pedersen Murine Leukemia Virus Proviral Insertions between the N-ras and unr Genes in B-Cell Lymphoma DNA Affect the Expression of N-ras Only J. Virol., December 1, 2001; 75(23): 11907 - 11912. [Abstract] [Full Text]